An in-depth analysis of the solid forms of the anticoagulant drug Apixaban (APX) has been
conducted to sort out the confusion in the scientific and patent literature regarding the solid
forms landscape. The nomenclature employed and the accompanying characterization data
are often unclear and incomplete, leading to a situation in which apparently the same form
has been reported by different authors or claimed by different inventors. A comprehensive
solid forms screen and a full and careful comparison with the literature data has been …